Breaking News

Compugen, Bayer Advance Cancer Immunotherapy

Compugen to manufacture COM902 for clinical trials

Compugen Ltd., a company focused on predictive discovery and development of therapeutics for cancer immunotherapy, has advanced COM902, its lead anti-TIGIT antibody, into manufacturing for an investigational new drug (IND) application anticipated in 2019.   The company has entered into a process development and manufacturing service agreement with Bayer to produce COM902 for future use in clinical trials.   Sunil Gupta, the vice president of Biological Development at Bayer, said, “As a compa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters